CN119212702A - 用于治疗癌症的组合疗法 - Google Patents

用于治疗癌症的组合疗法 Download PDF

Info

Publication number
CN119212702A
CN119212702A CN202380032432.8A CN202380032432A CN119212702A CN 119212702 A CN119212702 A CN 119212702A CN 202380032432 A CN202380032432 A CN 202380032432A CN 119212702 A CN119212702 A CN 119212702A
Authority
CN
China
Prior art keywords
azd5305
pharmaceutically acceptable
acceptable salt
enzalutamide
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380032432.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·C·科苏利奇
M·R·阿尔伯特拉
J·S·布朗
E·李奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN119212702A publication Critical patent/CN119212702A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380032432.8A 2022-04-07 2023-04-06 用于治疗癌症的组合疗法 Pending CN119212702A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263362613P 2022-04-07 2022-04-07
US63/362613 2022-04-07
PCT/EP2023/059130 WO2023194530A1 (en) 2022-04-07 2023-04-06 Combination therapy for treating cancer

Publications (1)

Publication Number Publication Date
CN119212702A true CN119212702A (zh) 2024-12-27

Family

ID=86226547

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380032432.8A Pending CN119212702A (zh) 2022-04-07 2023-04-06 用于治疗癌症的组合疗法

Country Status (11)

Country Link
US (1) US20250213556A1 (https=)
EP (1) EP4504182A1 (https=)
JP (1) JP2025511402A (https=)
KR (1) KR20240170957A (https=)
CN (1) CN119212702A (https=)
AU (1) AU2023250031A1 (https=)
CA (1) CA3254949A1 (https=)
IL (1) IL316017A (https=)
MX (1) MX2024012392A (https=)
TW (1) TW202404661A (https=)
WO (1) WO2023194530A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202600137A (zh) * 2024-04-04 2026-01-01 美商輝瑞股份有限公司 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705903B2 (en) 1994-08-12 2009-08-12 The University of Utah Research Foundation Mutations in the 17q-linked breast and ovarian cancer susceptibility gene
DK0699754T3 (da) 1994-08-12 2001-02-26 Myriad Genetics Inc Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
MX2022000711A (es) 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.

Also Published As

Publication number Publication date
JP2025511402A (ja) 2025-04-15
KR20240170957A (ko) 2024-12-05
CA3254949A1 (en) 2023-10-12
IL316017A (en) 2024-11-01
EP4504182A1 (en) 2025-02-12
TW202404661A (zh) 2024-02-01
WO2023194530A1 (en) 2023-10-12
US20250213556A1 (en) 2025-07-03
AU2023250031A1 (en) 2024-11-14
MX2024012392A (es) 2024-11-08

Similar Documents

Publication Publication Date Title
US20210000810A1 (en) Pharmaceutical combination comprising lsz102 and alpelisib
CN119212702A (zh) 用于治疗癌症的组合疗法
CN118973572A (zh) 用于治疗癌症的组合疗法
KR20220124739A (ko) 암의 치료를 위한 병용 요법
US20250228847A1 (en) Combination therapy for treating cancer
CN118678960A (zh) 用于治疗癌症的方法和组合物
KR20260010420A (ko) 암 치료를 위한 parp1 억제제 및 선택적 에스트로겐 분해제의 병용
EP4364742A1 (en) Pharmaceutical composition for treating solid tumors
AU2002366975B2 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
KR20260020107A (ko) 다발성 경화증을 치료하기 위한 btk 억제제
KR20240148328A (ko) 전이성 거세 저항성 전립선암 및 hrr 변형을 갖는 환자에서 임상 결과를 개선하기 위한 니라파립 및 아비라테론 아세테이트와 프레드니손
US20090062246A1 (en) Therapeutic treatment-014
CN118542942A (zh) Pd-l1小分子抑制剂与抗体的药物组合及其应用
HK1204976A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination